




RealRate

PHARMACEUTICAL 2019

Moleculin Biotech Inc.
Rank 180 of 363





RealRate

PHARMACEUTICAL 2019

Moleculin Biotech Inc.
Rank 180 of 363



The relative strengths and weaknesses of Moleculin Biotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Moleculin Biotech Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 160% points. The greatest weakness of Moleculin Biotech Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 102%, being 65% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	7,974
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,878
Liabilities, Non-Current	0
Other Assets	11,148
Other Compr. Net Income	35
Other Expenses	-3,117
Other Liabilities	1,435
Other Net Income	-36
Other Revenues	0
Property and Equipment	463
Research and Development	9,728
Selling, General and Administrative Expense	5,229

Output Variable	Value in 1000 USD
Assets	19,585
Liabilities	5,313
Expenses	11,840
Revenues	0
Stockholders Equity	14,272
Net Income	-11,876
Comprehensive Net Income	-11,858
Economic Capital Ratio	102%